ABBVIE INC. (NYSE:ABBV) Files An 8-K Results of Operations and Financial ConditionItem 2.02Results of Operations and Financial Condition
On November2, 2018, AbbVie Inc. issued a press release announcing financial results for the third quarter ended September30, 2018. A copy of the press release is furnished as Exhibit99.1 to this report and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
AbbVie Inc. ExhibitEX-99 2 abbv-20180930xexhibit991.htm EXHIBIT 99.1 Exhibit Exhibit 99.1 PRESS RELEASE AbbVie Reports Third-Quarter 2018 Financial Results •Reports Third-Quarter Diluted EPS of $1.81 on a GAAP Basis; Adjusted Diluted EPS of $2.14 Reflects Growth of 51.8 Percent•Delivers Third-Quarter Net Revenues of $8.236 Billion on a GAAP Basis; Adjusted Net Revenues of $8.236 Billion Increased 18.5 Percent on an Operational Basis•Third-Quarter Global HUMIRA Sales of $5.124 Billion Increased 9.0 Percent on a Reported Basis,…To view the full exhibit click here
About ABBVIE INC. (NYSE:ABBV)
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company operates in pharmaceutical products segment. Its products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, as well as other serious health conditions. AbbVie also has a pipeline of new medicines, including over 50 compounds or indications, such as immunology, virology/liver disease, oncology, neurological diseases and women’s health. Its product portfolio includes HUMIRA, IMBRUVICA, HCV products, additional virology products, metabolics/hormones products, endocrinology products and other products.
